DelveInsight’s “Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obsessive Compulsive Disorder Market Forecast
Some of the key facts of the Obsessive Compulsive Disorder Market Report:
The Obsessive Compulsive Disorder market size was valued approximately USD 1,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, Obsessive-compulsive disorder (OCD) can be highly resistant to standard therapies, significantly affecting patients’ quality of life. In a groundbreaking effort, researchers conducted the first-ever clinical trial using magnetic resonance-guided focused ultrasound (MRgFUS) capsulotomy for individuals with treatment-resistant OCD. A decade-long follow-up revealed lasting symptom relief, improved daily functioning, and strong patient satisfaction. These findings highlight MRgFUS capsulotomy as a promising, safe, and effective treatment option, bringing renewed hope to OCD patients globally.
In 2023, the market size of Obsessive Compulsive Disorder in the United States was approximately USD 600 million.
In 2023, selective serotonin reuptake inhibitors (SSRIs) generated roughly USD 290 million in revenue across the seven major markets, while antipsychotics followed, earning around USD 160 million.
In 2023, the market size for Obsessive Compulsive Disorder in the EU4 countries and the UK was approximately USD 380 million.
In 2023, the United States had approximately 2.1 million diagnosed prevalent cases of Obsessive Compulsive Disorder.
In 2023, the 7MM had around 320,000 mild cases, 760,000 moderate cases, and 1,100,000 severe cases of Obsessive Compulsive Disorder.
In 2023, approximately 22% of Obsessive Compulsive Disorder cases in the EU4 and the UK were male, while about 78% were female.
Key Obsessive Compulsive Disorder Companies: Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others
Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim®, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others
The Obsessive Compulsive Disorder epidemiology based on gender analyzed that the occurrence of gender-specific cases of Obsessive Compulsive Disorder is more in females than in males
The Obsessive Compulsive Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obsessive Compulsive Disorder pipeline products will significantly revolutionize the Obsessive Compulsive Disorder market dynamics.
Obsessive Compulsive Disorder Overview
Obsessive-Compulsive Disorder (OCD) is a mental health condition characterized by persistent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions) performed to alleviate anxiety. These behaviors often interfere with daily activities and can significantly impact an individual’s quality of life. Common obsessions include fears of contamination or harm, while compulsions might involve excessive cleaning, checking, or organizing. OCD affects both adults and children and typically requires treatment through therapy, medication, or a combination of both to manage symptoms effectively.
Get a Free sample for the Obsessive Compulsive Disorder Market Report –
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market
Obsessive Compulsive Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Obsessive Compulsive Disorder Epidemiology Segmentation:
The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Obsessive Compulsive Disorder
Prevalent Cases of Obsessive Compulsive Disorder by severity
Gender-specific Prevalence of Obsessive Compulsive Disorder
Diagnosed Cases of Episodic and Chronic Obsessive Compulsive Disorder
Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ Obsessive Compulsive Disorder Epidemiology Forecast
Obsessive Compulsive Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obsessive Compulsive Disorder market or expected to get launched during the study period. The analysis covers Obsessive Compulsive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Obsessive Compulsive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Obsessive Compulsive Disorder Therapies and Key Companies
Troriluzole: Biohaven Pharmaceuticals, Inc.
Fluvoxamine maleate: AbbVie
BHV-4157: Biohaven Pharmaceuticals, Inc.
Quetiapine: AstraZeneca
Reclaim®: MedtronicNeuro
Bitopertin: Hoffmann-La Roche
topiramate: Ortho-McNeil Pharmaceutical
Escitalopram: Forest Laboratories
Duloxetine: Eli Lilly and Company
Topiramate: Janssen-Ortho Inc
Paliperidone: Ortho-McNeil Janssen Scientific
pregabalin: Pfizer
Discover more about therapies set to grab major Obsessive Compulsive Disorder market share @ Obsessive Compulsive Disorder Treatment Market
Obsessive Compulsive Disorder Market Drivers
Negative lifestyle practices like unhealthy eating habits,smoking, lack of abundant sleep, and sedentary routine further proliferate anxiety disorders among individuals.
Even though the emerging pipeline for OCD is not robust, the expected approval of troriluzole, a late-stage drug candidate with novel MoA, would drive the market.
Obsessive Compulsive Disorder Market Barriers
SRIs, antipsychotics, mood stabilizers, and CBT are the mainstay of treatment for OCD. Therapies with novel MoAs are required to exhibit better efficacy and fewer side effects.
Although several clinical, environmental, and biological predictors of response have been reported, delivering more personalized treatments for OCD is not a reality thus far.
Scope of the Obsessive Compulsive Disorder Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Obsessive Compulsive Disorder Therapeutic Assessment: Obsessive Compulsive Disorder current marketed and Obsessive Compulsive Disorder emerging therapies
Obsessive Compulsive Disorder Market Dynamics: Obsessive Compulsive Disorder market drivers and Obsessive Compulsive Disorder market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Obsessive Compulsive Disorder Unmet Needs, KOL’s views, Analyst’s views, Obsessive Compulsive Disorder Market Access and Reimbursement
To know more about Obsessive Compulsive Disorder companies working in the treatment market, visit @ Obsessive Compulsive Disorder Clinical Trials and Therapeutic Assessment
Table of Contents
1. Obsessive Compulsive Disorder Market Report Introduction
2. Executive Summary for Obsessive Compulsive Disorder
3. SWOT analysis of Obsessive Compulsive Disorder
4. Obsessive Compulsive Disorder Patient Share (%) Overview at a Glance
5. Obsessive Compulsive Disorder Market Overview at a Glance
6. Obsessive Compulsive Disorder Disease Background and Overview
7. Obsessive Compulsive Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Obsessive Compulsive Disorder
9. Obsessive Compulsive Disorder Current Treatment and Medical Practices
10. Obsessive Compulsive Disorder Unmet Needs
11. Obsessive Compulsive Disorder Emerging Therapies
12. Obsessive Compulsive Disorder Market Outlook
13. Country-Wise Obsessive Compulsive Disorder Market Analysis (2020–2034)
14. Obsessive Compulsive Disorder Market Access and Reimbursement of Therapies
15. Obsessive Compulsive Disorder Market Drivers
16. Obsessive Compulsive Disorder Market Barriers
17. Obsessive Compulsive Disorder Appendix
18. Obsessive Compulsive Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
